MiMedx Group, Inc. (NASDAQ: MDXG) Stock Competitors & Peer Comparison
See MDXG's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MDXG and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDXG | $4.71 | +1.40% | 688M | 13.88 | $0.34 | N/A |
| VRTX | $515.85 | -0.70% | 130.6B | 27.04 | $19.03 | N/A |
| REGN | $778.52 | -1.92% | 79.8B | 16.96 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $980.40 | -1.02% | 60.9B | 88.43 | $11.08 | N/A |
| MRNA | $146.41 | -0.19% | 57B | -17.64 | -$8.15 | N/A |
| RVMDW | $10.61 | -7.21% | 44.6B | -1.29 | -$8.82 | N/A |
| RVMD | $199.21 | -2.88% | 43.6B | -23.27 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $346.80 | -1.99% | 37B | 61.00 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
MDXG vs VRTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, VRTX has a market cap of 130.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while VRTX trades at $515.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas VRTX's P/E ratio is 27.04. In terms of profitability, MDXG's ROE is +0.03%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, MDXG is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
MDXG vs REGN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, REGN has a market cap of 79.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while REGN trades at $778.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas REGN's P/E ratio is 16.96. In terms of profitability, MDXG's ROE is +0.03%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MDXG is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
MDXG vs VRNA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MDXG's ROE is +0.03%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MDXG is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
MDXG vs ARGX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ARGX has a market cap of 60.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ARGX trades at $980.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ARGX's P/E ratio is 88.43. In terms of profitability, MDXG's ROE is +0.03%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, MDXG is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
MDXG vs MRNA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MRNA has a market cap of 57B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MRNA trades at $146.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MRNA's P/E ratio is -17.64. In terms of profitability, MDXG's ROE is +0.03%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, MDXG is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
MDXG vs RVMDW Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RVMDW has a market cap of 44.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RVMDW trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, MDXG's ROE is +0.03%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, MDXG is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
MDXG vs RVMD Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RVMD trades at $199.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RVMD's P/E ratio is -23.27. In terms of profitability, MDXG's ROE is +0.03%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, MDXG is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
MDXG vs SGEN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MDXG's ROE is +0.03%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MDXG is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
MDXG vs ONC Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ONC has a market cap of 37B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ONC trades at $346.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ONC's P/E ratio is 61.00. In terms of profitability, MDXG's ROE is +0.03%, compared to ONC's ROE of +0.14%. Regarding short-term risk, MDXG is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
MDXG vs ALNY Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ALNY has a market cap of 31.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ALNY trades at $240.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ALNY's P/E ratio is 42.93. In terms of profitability, MDXG's ROE is +0.03%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, MDXG is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
MDXG vs ROIV Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ROIV has a market cap of 28.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ROIV trades at $40.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ROIV's P/E ratio is -37.58. In terms of profitability, MDXG's ROE is +0.03%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, MDXG is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
MDXG vs INSM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, INSM has a market cap of 26B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while INSM trades at $122.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas INSM's P/E ratio is -29.18. In terms of profitability, MDXG's ROE is +0.03%, compared to INSM's ROE of -1.11%. Regarding short-term risk, MDXG is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
MDXG vs INCY Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while INCY trades at $123.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas INCY's P/E ratio is 16.36. In terms of profitability, MDXG's ROE is +0.03%, compared to INCY's ROE of +0.30%. Regarding short-term risk, MDXG is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
MDXG vs BNTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BNTX trades at $96.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BNTX's P/E ratio is -12.54. In terms of profitability, MDXG's ROE is +0.03%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, MDXG is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
MDXG vs UTHR Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, UTHR has a market cap of 21.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while UTHR trades at $502.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas UTHR's P/E ratio is 17.90. In terms of profitability, MDXG's ROE is +0.03%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, MDXG is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
MDXG vs GMAB Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, GMAB has a market cap of 21B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while GMAB trades at $34.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas GMAB's P/E ratio is 25.73. In terms of profitability, MDXG's ROE is +0.03%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, MDXG is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
MDXG vs BGNE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MDXG's ROE is +0.03%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, MDXG is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
MDXG vs DNA-WT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MDXG's ROE is +0.03%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, MDXG is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
MDXG vs JAZZ Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while JAZZ trades at $242.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, MDXG's ROE is +0.03%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, MDXG is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
MDXG vs NBIX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, NBIX has a market cap of 15.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while NBIX trades at $150.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas NBIX's P/E ratio is 21.68. In terms of profitability, MDXG's ROE is +0.03%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, MDXG is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
MDXG vs ASND Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ASND has a market cap of 14.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ASND trades at $246.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ASND's P/E ratio is -99.08. In terms of profitability, MDXG's ROE is +0.03%, compared to ASND's ROE of +1.90%. Regarding short-term risk, MDXG is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
MDXG vs EXEL Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while EXEL trades at $57.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas EXEL's P/E ratio is 16.26. In terms of profitability, MDXG's ROE is +0.03%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, MDXG is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
MDXG vs SMMT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, SMMT has a market cap of 13.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while SMMT trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas SMMT's P/E ratio is -15.54. In terms of profitability, MDXG's ROE is +0.03%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, MDXG is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
MDXG vs BBIO Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BBIO trades at $69.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BBIO's P/E ratio is -18.29. In terms of profitability, MDXG's ROE is +0.03%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, MDXG is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
MDXG vs HALO Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, HALO has a market cap of 12.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while HALO trades at $107.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas HALO's P/E ratio is 19.82. In terms of profitability, MDXG's ROE is +0.03%, compared to HALO's ROE of +1.81%. Regarding short-term risk, MDXG is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
MDXG vs KRTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MDXG's ROE is +0.03%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MDXG is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
MDXG vs BMRN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BMRN has a market cap of 12.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BMRN trades at $64.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BMRN's P/E ratio is 30.99. In terms of profitability, MDXG's ROE is +0.03%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, MDXG is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
MDXG vs MDGL Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MDGL trades at $523.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MDGL's P/E ratio is -40.88. In terms of profitability, MDXG's ROE is +0.03%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, MDXG is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
MDXG vs TECH Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TECH trades at $72.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TECH's P/E ratio is 37.29. In terms of profitability, MDXG's ROE is +0.03%, compared to TECH's ROE of +0.09%. Regarding short-term risk, MDXG is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
MDXG vs RNAM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MDXG's ROE is +0.03%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MDXG is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
MDXG vs AXSM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, AXSM has a market cap of 10.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while AXSM trades at $212.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas AXSM's P/E ratio is -53.28. In terms of profitability, MDXG's ROE is +0.03%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, MDXG is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
MDXG vs ARWR Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ARWR has a market cap of 10B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ARWR trades at $67.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ARWR's P/E ratio is -31.41. In terms of profitability, MDXG's ROE is +0.03%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, MDXG is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ARWR's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
MDXG vs KRYS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while KRYS trades at $343.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas KRYS's P/E ratio is 42.19. In terms of profitability, MDXG's ROE is +0.03%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MDXG is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
MDXG vs RXDX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MDXG's ROE is +0.03%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MDXG is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check RXDX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
MDXG vs TXG Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TXG has a market cap of 9.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TXG trades at $74.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TXG's P/E ratio is -126.08. In terms of profitability, MDXG's ROE is +0.03%, compared to TXG's ROE of -0.09%. Regarding short-term risk, MDXG is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
MDXG vs KYMR Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, KYMR has a market cap of 9.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while KYMR trades at $115.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas KYMR's P/E ratio is -35.36. In terms of profitability, MDXG's ROE is +0.03%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, MDXG is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
MDXG vs PTGX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PTGX trades at $143.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PTGX's P/E ratio is 139.22. In terms of profitability, MDXG's ROE is +0.03%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, MDXG is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
MDXG vs NUVL Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MDXG's ROE is +0.03%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MDXG is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
MDXG vs CRNX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CRNX's P/E ratio is -16.86. In terms of profitability, MDXG's ROE is +0.03%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MDXG is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
MDXG vs IMGN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MDXG's ROE is +0.03%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MDXG is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check IMGN's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
MDXG vs PRAX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PRAX has a market cap of 8.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PRAX trades at $312.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PRAX's P/E ratio is -24.20. In terms of profitability, MDXG's ROE is +0.03%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, MDXG is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PRAX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
MDXG vs CYTK Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CYTK trades at $70.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CYTK's P/E ratio is -9.60. In terms of profitability, MDXG's ROE is +0.03%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, MDXG is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check CYTK's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
MDXG vs TWST Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TWST has a market cap of 8.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TWST trades at $145.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TWST's P/E ratio is -62.21. In terms of profitability, MDXG's ROE is +0.03%, compared to TWST's ROE of -0.30%. Regarding short-term risk, MDXG is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TWST's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
MDXG vs PCVX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PCVX trades at $59.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PCVX's P/E ratio is -7.76. In terms of profitability, MDXG's ROE is +0.03%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, MDXG is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
MDXG vs IBRX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while IBRX trades at $8.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas IBRX's P/E ratio is -8.39. In terms of profitability, MDXG's ROE is +0.03%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, MDXG is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check IBRX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
MDXG vs BPMC Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MDXG's ROE is +0.03%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MDXG is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
MDXG vs APGE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas APGE's P/E ratio is -31.19. In terms of profitability, MDXG's ROE is +0.03%, compared to APGE's ROE of -0.30%. Regarding short-term risk, MDXG is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
MDXG vs CERE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CERE's P/E ratio is -16.47. In terms of profitability, MDXG's ROE is +0.03%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MDXG is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
MDXG vs TGTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TGTX has a market cap of 8.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TGTX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TGTX's P/E ratio is 19.22. In terms of profitability, MDXG's ROE is +0.03%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, MDXG is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TGTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
MDXG vs CAI Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CAI has a market cap of 8.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CAI trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CAI's P/E ratio is 80.08. In terms of profitability, MDXG's ROE is +0.03%, compared to CAI's ROE of +0.19%. Regarding short-term risk, MDXG is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check CAI's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
MDXG vs SYRE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while SYRE trades at $91.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas SYRE's P/E ratio is -46.64. In terms of profitability, MDXG's ROE is +0.03%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, MDXG is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check SYRE's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
MDXG vs IONS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, IONS has a market cap of 7.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while IONS trades at $46.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas IONS's P/E ratio is -27.47. In terms of profitability, MDXG's ROE is +0.03%, compared to IONS's ROE of -1.11%. Regarding short-term risk, MDXG is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
MDXG vs ABVX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ABVX has a market cap of 7.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ABVX trades at $104.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ABVX's P/E ratio is -55.91. In terms of profitability, MDXG's ROE is +0.03%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MDXG is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
MDXG vs IMVT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while IMVT trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas IMVT's P/E ratio is -13.00. In terms of profitability, MDXG's ROE is +0.03%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, MDXG is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
MDXG vs MTSR Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MDXG's ROE is +0.03%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MDXG is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
MDXG vs MRUS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MDXG's ROE is +0.03%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MDXG is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check MRUS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
MDXG vs BLTE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while BLTE trades at $170.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas BLTE's P/E ratio is -90.61. In terms of profitability, MDXG's ROE is +0.03%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, MDXG is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check BLTE's competition here
Arcellx, Inc. (NASDAQ: ACLX)
MDXG vs ACLX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MDXG's ROE is +0.03%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MDXG is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
MDXG vs RYTM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RYTM trades at $99.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RYTM's P/E ratio is -31.12. In terms of profitability, MDXG's ROE is +0.03%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, MDXG is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check RYTM's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
MDXG vs RETA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RETA's P/E ratio is -66.29. In terms of profitability, MDXG's ROE is +0.03%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MDXG is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
MDXG vs CGON Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CGON trades at $73.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CGON's P/E ratio is -26.97. In terms of profitability, MDXG's ROE is +0.03%, compared to CGON's ROE of -0.25%. Regarding short-term risk, MDXG is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
MDXG vs CNTA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MDXG's ROE is +0.03%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MDXG is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CNTA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
MDXG vs SRRK Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, SRRK has a market cap of 6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while SRRK trades at $49.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas SRRK's P/E ratio is -14.49. In terms of profitability, MDXG's ROE is +0.03%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, MDXG is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check SRRK's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
MDXG vs DNTH Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while DNTH trades at $104.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas DNTH's P/E ratio is -25.25. In terms of profitability, MDXG's ROE is +0.03%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, MDXG is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
MDXG vs TVTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TVTX trades at $63.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TVTX's P/E ratio is -138.91. In terms of profitability, MDXG's ROE is +0.03%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, MDXG is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
MDXG vs MIRM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MIRM trades at $97.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MIRM's P/E ratio is -6.45. In terms of profitability, MDXG's ROE is +0.03%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, MDXG is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check MIRM's competition here
Erasca, Inc. (NASDAQ: ERAS)
MDXG vs ERAS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ERAS trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ERAS's P/E ratio is -17.47. In terms of profitability, MDXG's ROE is +0.03%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, MDXG is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ERAS's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
MDXG vs LGND Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while LGND trades at $274.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas LGND's P/E ratio is 30.81. In terms of profitability, MDXG's ROE is +0.03%, compared to LGND's ROE of +0.20%. Regarding short-term risk, MDXG is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
MDXG vs CDTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MDXG's ROE is +0.03%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MDXG is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CDTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
MDXG vs COGT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while COGT trades at $32.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas COGT's P/E ratio is -15.52. In terms of profitability, MDXG's ROE is +0.03%, compared to COGT's ROE of -0.73%. Regarding short-term risk, MDXG is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check COGT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
MDXG vs ORKA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ORKA trades at $93.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ORKA's P/E ratio is -47.53. In terms of profitability, MDXG's ROE is +0.03%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, MDXG is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
MDXG vs ABCM Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MDXG's ROE is +0.03%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MDXG is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
MDXG vs ISEE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MDXG's ROE is +0.03%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MDXG is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
MDXG vs PTCT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PTCT trades at $67.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PTCT's P/E ratio is -28.18. In terms of profitability, MDXG's ROE is +0.03%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, MDXG is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PTCT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
MDXG vs XENE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, XENE has a market cap of 5.4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while XENE trades at $57.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas XENE's P/E ratio is -11.97. In terms of profitability, MDXG's ROE is +0.03%, compared to XENE's ROE of -0.44%. Regarding short-term risk, MDXG is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check XENE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
MDXG vs APLS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas APLS's P/E ratio is 38.35. In terms of profitability, MDXG's ROE is +0.03%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MDXG is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
MDXG vs CRSP Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CRSP trades at $52.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CRSP's P/E ratio is -10.89. In terms of profitability, MDXG's ROE is +0.03%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, MDXG is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
MDXG vs DFTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while DFTX trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas DFTX's P/E ratio is N/A. In terms of profitability, MDXG's ROE is +0.03%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, MDXG is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check DFTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
MDXG vs TERN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TERN's P/E ratio is -51.41. In terms of profitability, MDXG's ROE is +0.03%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MDXG is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
MDXG vs EWTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while EWTX trades at $44.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas EWTX's P/E ratio is -23.58. In terms of profitability, MDXG's ROE is +0.03%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, MDXG is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check EWTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
MDXG vs ACAD Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ACAD has a market cap of 4.6B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ACAD trades at $27.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ACAD's P/E ratio is 12.05. In terms of profitability, MDXG's ROE is +0.03%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, MDXG is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
MDXG vs FOLD Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MDXG's ROE is +0.03%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MDXG is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
MDXG vs AKRO Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MDXG's ROE is +0.03%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MDXG is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
MDXG vs ALPN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MDXG's ROE is +0.03%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MDXG is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check ALPN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
MDXG vs TLX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TLX trades at $12.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TLX's P/E ratio is 133.92. In terms of profitability, MDXG's ROE is +0.03%, compared to TLX's ROE of +0.07%. Regarding short-term risk, MDXG is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
MDXG vs ADPT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ADPT has a market cap of 4.3B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ADPT trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ADPT's P/E ratio is -65.07. In terms of profitability, MDXG's ROE is +0.03%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, MDXG is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ADPT's competition here
Veradermics, Incorporated (NYSE: MANE)
MDXG vs MANE Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MANE trades at $103.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MANE's P/E ratio is -32.36. In terms of profitability, MDXG's ROE is +0.03%, compared to MANE's ROE of -0.38%. Regarding short-term risk, MDXG is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
MDXG vs OPT Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas OPT's P/E ratio is -1.52. In terms of profitability, MDXG's ROE is +0.03%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MDXG is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
MDXG vs PRTC Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PRTC's P/E ratio is -3.78. In terms of profitability, MDXG's ROE is +0.03%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, MDXG is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PRTC's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
MDXG vs IOVA Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, IOVA has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while IOVA trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas IOVA's P/E ratio is -12.82. In terms of profitability, MDXG's ROE is +0.03%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, MDXG is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check IOVA's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
MDXG vs PBLS Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, PBLS has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while PBLS trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas PBLS's P/E ratio is -40.59. In terms of profitability, MDXG's ROE is +0.03%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, MDXG is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check PBLS's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
MDXG vs RLAY Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RLAY trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RLAY's P/E ratio is -12.08. In terms of profitability, MDXG's ROE is +0.03%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, MDXG is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
MDXG vs MRTX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MDXG's ROE is +0.03%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MDXG is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
MDXG vs CELC Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CELC trades at $82.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CELC's P/E ratio is -19.23. In terms of profitability, MDXG's ROE is +0.03%, compared to CELC's ROE of -3.51%. Regarding short-term risk, MDXG is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check CELC's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
MDXG vs TNGX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while TNGX trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas TNGX's P/E ratio is -28.78. In terms of profitability, MDXG's ROE is +0.03%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, MDXG is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
MDXG vs CPRX Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CPRX's P/E ratio is 12.30. In terms of profitability, MDXG's ROE is +0.03%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MDXG is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
MDXG vs ELVN Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while ELVN trades at $50.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas ELVN's P/E ratio is -31.95. In terms of profitability, MDXG's ROE is +0.03%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, MDXG is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for MDXG.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
MDXG vs RYZB Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MDXG's ROE is +0.03%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MDXG is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
MDXG vs CBAY Comparison September 2026
MiMedx Group, Inc. (NASDAQ: MDXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDXG stands at 688M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MDXG is priced at $4.71 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDXG currently has a P/E ratio of 13.88, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MDXG's ROE is +0.03%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MDXG is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for MDXG.Check CBAY's competition here